In accordance with applicable privacy legislation, the company Kedrion S.p.a., controller of the data acquired via this website, hereby informs the user that said website does not use profiling cookies to send advertising messages tuned to preferences expressed when browsing the internet. This website installs third party cookies. Continuing to browse, including by scrolling down and clicking on website elements, equates to consent.
For more information, also as regards the technical cookies used by the website and to refuse consent to the installation of individual cookies, please refer to the complete cookies disclosure.
You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES
-
CORPORATE - 31-10-2017
Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy
Agreement covers complete INTERCEPT product line: platelets, plasma and red blood cells
read more -
CORPORATE - 25-08-2017
Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®
The product is approved for post-exposure prophylaxis against rabies infection
read more -
CORPORATE - 19-04-2017
Kedrion Biopharma signs agreement with European Hemophilia Consortium (EHC)
The agreement aims to improve patient access to coagulation disorders treatments in Europe
read more -
CORPORATE - 24-03-2017
New company AO Kirov Plasma established in Russia
It’s a joint venture between Kedrion Biopharma, Nacimbio and Pharmastandard
read more
For more information please contact: pressoffice@kedrion.com
Where 